Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Search History:
Count: 75
Selected: 0
NCT IDTitle
NCT06449664Training for Men Undergoing Androgen Deprivation Therapy.
NCT03477864Stereotactic Body Radiation Therapy With REGN2810 and/or Ipilimumab Before Surgery in Treating Participants With Progressive Advanced or Oligometastatic Prostate Cancer
NCT03007732Pembrolizumab +/- SD-101 in Hormone-Naïve Oligometastatic Prostate Cancer With RT and iADT
NCT06424275Prostate Cancer Awareness and Initiative for Screening in the European Union
NCT02985021Docetaxel and Carboplatin for Patients With mCRPC and DNA-Repair Deficiencies
NCT02470936Web-based Lifestyle Trial Among Men With Prostate Cancer: Prostate 8
NCT02080650Characterization of Circulating Tumor Cells Captured by c-MET (CTC-MET)
NCT04824937Telaglenastat + Talazoparib In Prostate Cancer
NCT01703065Cabozantinib in Men With Castration-Resistant Prostate Cancer
NCT05078151Whole-Body Diffusion-Weighted Magnetic Resonance Imaging (MRI) as a Response Biomarker for Metastatic Prostate Cancer
NCT03031821Metformin in Patients Initiating ADT as Prevention and Intervention of Metabolic Syndrome
NCT02582697Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours
NCT05445609Vidutolimod (CMP-001) in Combination With Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer
NCT01417182Biodistribution and Pharmacokinetic Study of 18F-DCFBC Prostate Specific Membrane Antigen Based PET in Patients With Advanced Prostate Cancer
NCT06200974Multi-omic Approach to Study HDR Brachytherapy for Favorable Risk and Low Tier Intermediate Risk Prostate Cancer
NCT06714630The PROSECCA Study, Answering New Questions in Prostate Cancer
NCT03392428A Trial of 177Lu-PSMA617 Theranostic Versus Cabazitaxel in Progressive Metastatic Castration Resistant Prostate Cancer
NCT00651222Influence of Hormone Therapy on Heart Attack Incidence in Men Undergoing Prostate Brachytherapy
NCT05766371Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer
NCT06171139Tumor Genomic Pre-test Counseling Tool for Black or African-American Men With Prostate Cancer
NCT02735252PROMOTE: Identifying Predictive Markers of Response for Genitourinary Cancer
NCT04090528pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer
NCT05765500RecoverPC: Relugolix vs GnRH Agonist in Quality of Life
NCT03276572Phase I Trial of 225Ac-J591 in Patients With mCRPC
NCT00744549Study of Antioxidants on MRI Detectable Early Stage Prostate Cancer Among Men on Active Surveillance
NCT01289067Utilizing A Genomic Sig for "BRCAness" to Eval the Efficacy of Satraplatin in Men With Met. Castration Resistant Prostate Ca
NCT0471672568Ga-PSMA-11 PET for the Diagnosis of Metastatic Castration Resistant Prostate Cancer
NCT01950143Effect of Sulforaphane on Prostate CAncer PrEvention
NCT03805594177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
NCT05435495Mechanisms of Resistance to PSMA Radioligand Therapy
NCT00156884A Trial of Strontium +/- Cisplatin for the Palliation of Bone Pain Secondary to Hormone Refractory Prostate Cancer
NCT07050433COMPASS Study for Metastatic Castration-resistant Prostate Cancer
NCT05113537Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer
NCT05918263Exercise for Tumor Suppressive Impact in Black Men With Prostate Cancer on Active Surveillance: The REMOVE Trial
NCT04457232Prospective Exploratory Study of FAPi PET/CT in Prostate Cancer With Histopathology Validation
NCT02881242Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer
NCT02499835Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer
NCT04447703Technology-Enhanced Acceleration of Germline Evaluation for Therapy, TARGET Study
NCT02856100Comparison of PSMA-based 18F-DCFPyL PET/CT to Conventional Imaging in the Evaluation of Patients With Castration-Resistant Prostate Cancer
NCT02269982Prospective CiRculating prOstate Cancer Predictors in HighEr Risk mCRPC studY
NCT02677376Imaging Biomarkers to Validate Response in Enzalutamide-Treated mCRPC
NCT02135484Radium 223 in Castrate Resistant Prostate Cancer Bone Metastases
NCT04343885In Men With Metastatic Prostate Cancer, What is the Safety and Benefit of Lutetium-177 PSMA Radionuclide Treatment in Addition to Chemotherapy
NCT03492424Ablative Therapy in the Management of Prostate Cancer
NCT07002320Investigating SX-682 in Combination With Apalutamide in Metastatic Castration-resistant Prostate Cancer
NCT05320406RElugolix VErsus LeUprolide Cardiac Trial
NCT05702619Hypoxia-driven Prostate Cancer Genomics (HYPROGEN)
NCT02300324The Bioavailability Of Sulforaphane From Broccoli Soups Study (BOBS)
NCT05355727PROSAIC-DS Study (PROState AI in Cancer - Decision Support)
NCT03440554Non-contrast MR Imaging for Whole Body Cancer Detection and Characterization